Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-PT-CAR-NK-D
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-PT-CAR-NK-D is an allogeneic, donor-derived, dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy developed by Beijing Biotech for the treatment of advanced solid tumors. As part of a Phase 1/2 biomarker-guided platform study, the therapy is matched to two co-expressed tumor antigens identified through individual patient profiling using liquid or tissue biopsies. This dual-targeting strategy is intended to enhance therapeutic efficacy and mitigate the risk of tumor escape through antigen loss. The cells are administered intravenously following a lymphodepletion regimen consisting of fludarabine and cyclophosphamide, and the treatment is typically supported by cytokine agonists such as IL-2 or IL-15 to promote the expansion and persistence of the infused CAR-NK cells.
- Other names
- EB-PT-CAR-NK-D-Beijing Biotech
Beyond the preview
Go deeper on EB-PT-CAR-NK-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-PT-CAR-NK-D.